Changes in body weight and composition, metabolic parameters, and quality of life in patients with type 2 diabetes treated with subcutaneous semaglutide in real-world clinical practice.

Pantanetti P, Cangelosi G, Alberti S, Di Marco S, Michetti G, Cerasoli G, Di Giacinti M, Coacci S, Francucci N, Petrelli F, Ambrosio G, Grinta R

Frontiers in endocrinology2 Jul 2024Cited by 29 (Europe PMC)

PMID39015186PMCIDPMC11250060DOI10.3389/fendo.2024.1394506PepBankPUB-39015186

Download PDF PubMedAsk about this study

Jump to 14 results

Summary

Subcutaneous once-weekly (ow) semaglutide is a recent treatment option for type 2 diabetes (T2D) and obesity, but real-world data on weight loss and associated changes in body composition, nutrients intake, and quality of life are still scarce. This observational, prospective clinical study involved all T2D patients starting ow semaglutide according to routine care between December 2021 and February 2022. Clinical information was collected after 6 months (T6) and 12 months (T12) from semaglutide initiation (T0). Bioelectrical Impedance Analysis (BIA) was performed to measure changes in body composition. Diabetes Treatment Satisfaction Questionnaire (DTSQ) and the 36 - items Short Form Health Survey (SF-36) were administered as patient-reported outcomes (PROs). Changes in continuous endpoints (weight, body composition, nutrients intake, other clinical parameters, and PROs) were assessed using mixed models for repeated measurements. Overall, 90 patients (age 63.0 ± 10.0 years; diabetes duration 7.6 ± 5.9 years; 58.9% men; HbA1c 7.7 ± 1.1%; weight 95.4 ± 19.4 Kg, BMI 34.6 ± 6.4 Kg/m²; 36.7% naïve to diabetes treatment, 43.3% on metformin, 10.0% on dual oral therapy, and 10.0% treated with schemes including insulin) were included in the study. After 6 months from semaglutide initiation, body weight significantly decrease by -4.69 Kg (95%CI -6.19;-3.19) (primary endpoint). After 12 months, body weight was further reduced (-5.38 Kg; 95%CI -7.79;-2.97). At BIA, fat mass was significantly reduced by 2.1 Kg after 6 months but only slightly reduced after 12 months vs. baseline; lean mass was also significantly reduced by over 3 Kg both at 6 and 12 months. Intake of all nutrients declined in the first 6 months of therapy, although only lipids reduction reached the statistical significance (-6.73 g; p=0.02). Statistically significant improvements in BMI, waist circumference, glycemic control, blood pressure and lipid profile were documented. Satisfaction with treatment (DTSQ questionnaire) and mental health (MCS score of SF-36 questionnaire) significantly increased during the follow-up. The study documented real-world benefits of semaglutide for treating obesity in T2D subjects, with important changes on clinical and patient-reported outcomes. Loss of lean mass associated with weight loss warrants attention; parallel strategies to preserve skeletal muscle and improve physical function, i.e. nutritional education and structured exercise, are of great importance.

CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study14

14 results from studies that gave the peptide. 14 results from people.

01HumanObservational studyEfficacy outcome
In adults with type 2 diabetes, body weight fell significantly by 4.69 kg after 6 months of subcutaneous semaglutide.
In plain wordsIn adults with type 2 diabetes, body weight was lower after 6 months of semaglutide.
Peptide
Semaglutide
Outcome
DecreaseBody weight change at 6 months
Study
n = 90
Comparator
Baseline
Analysis
Primary
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · subcutaneous · 6 monthsAs given in this study (human).
Measurements
Weight change
−4.69 Kg
6 months
Source sentences
Summary
After 6 months from semaglutide initiation, body weight significantly decrease by -4.69 Kg (95%CI -6.19;-3.19) (primary endpoint).
2 context sentences(design, population, supporting numbers)
Summary · context
This observational, prospective clinical study involved all T2D patients starting ow semaglutide according to routine care between December 2021 and February 2022.
Summary · context
Overall, 90 patients (age 63.0 ± 10.0 years; diabetes duration 7.6 ± 5.9 years; 58.9% men; HbA1c 7.7 ± 1.1%; weight 95.4 ± 19.4 Kg, BMI 34.6 ± 6.4 Kg/m²; 36.7% naïve to diabetes treatment, 43.3% on metformin, 10.0% on dual oral therapy, and 10.0% treated with schemes including insulin) were included in the study.
Show in the study text Report a problemFND-3901518601
02HumanObservational studyEfficacy outcome
In adults with type 2 diabetes, body weight was further reduced, by 5.38 kg, after 12 months of subcutaneous semaglutide.
In plain wordsIn adults with type 2 diabetes, body weight was lower still after 12 months of semaglutide.
Peptide
Semaglutide
Outcome
DecreaseBody weight change at 12 months
Study
n = 90
Comparator
Baseline
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · subcutaneous · 12 monthsAs given in this study (human).
Measurements
Weight change
−5.38 Kg
12 months
Source sentences
Summary
After 12 months, body weight was further reduced (-5.38 Kg; 95%CI -7.79;-2.97).
2 context sentences(design, population, supporting numbers)
Summary · context
This observational, prospective clinical study involved all T2D patients starting ow semaglutide according to routine care between December 2021 and February 2022.
Summary · context
Overall, 90 patients (age 63.0 ± 10.0 years; diabetes duration 7.6 ± 5.9 years; 58.9% men; HbA1c 7.7 ± 1.1%; weight 95.4 ± 19.4 Kg, BMI 34.6 ± 6.4 Kg/m²; 36.7% naïve to diabetes treatment, 43.3% on metformin, 10.0% on dual oral therapy, and 10.0% treated with schemes including insulin) were included in the study.
Show in the study text Report a problemFND-3901518602
03HumanObservational studyEfficacy outcome
In adults with type 2 diabetes, fat mass measured by bioelectrical impedance fell significantly by 2.1 kg after 6 months of semaglutide.
In plain wordsIn adults with type 2 diabetes, body fat was lower after 6 months of semaglutide.
Peptide
Semaglutide
Outcome
DecreaseFat mass change at 6 months
Study
n = 90
Comparator
Baseline
Outcome group
Body composition · Metabolic and weight
Studied dose
Dose not stated · subcutaneous · 6 monthsAs given in this study (human).
Measurements
Fat mass change
−2.1 Kg
6 months
Source sentences
Summary
At BIA, fat mass was significantly reduced by 2.1 Kg after 6 months but only slightly reduced after 12 months vs. baseline; lean mass was also significantly reduced by over 3 Kg both at 6 and 12 months.
2 context sentences(design, population, supporting numbers)
Summary · context
This observational, prospective clinical study involved all T2D patients starting ow semaglutide according to routine care between December 2021 and February 2022.
Summary · context
Overall, 90 patients (age 63.0 ± 10.0 years; diabetes duration 7.6 ± 5.9 years; 58.9% men; HbA1c 7.7 ± 1.1%; weight 95.4 ± 19.4 Kg, BMI 34.6 ± 6.4 Kg/m²; 36.7% naïve to diabetes treatment, 43.3% on metformin, 10.0% on dual oral therapy, and 10.0% treated with schemes including insulin) were included in the study.
Show in the study text Report a problemFND-3901518603
04HumanObservational studyEfficacy outcome
In adults with type 2 diabetes, fat mass was only slightly reduced versus baseline after 12 months of semaglutide.
In plain wordsIn adults with type 2 diabetes, body fat was only slightly lower after 12 months of semaglutide.
Peptide
Semaglutide
Outcome
DecreaseFat mass change at 12 months
Study
n = 90
Comparator
Baseline
Outcome group
Body composition · Metabolic and weight
Studied dose
Dose not stated · subcutaneous · 12 monthsAs given in this study (human).
Source sentences
Summary
At BIA, fat mass was significantly reduced by 2.1 Kg after 6 months but only slightly reduced after 12 months vs. baseline; lean mass was also significantly reduced by over 3 Kg both at 6 and 12 months.
2 context sentences(design, population, supporting numbers)
Summary · context
This observational, prospective clinical study involved all T2D patients starting ow semaglutide according to routine care between December 2021 and February 2022.
Summary · context
Overall, 90 patients (age 63.0 ± 10.0 years; diabetes duration 7.6 ± 5.9 years; 58.9% men; HbA1c 7.7 ± 1.1%; weight 95.4 ± 19.4 Kg, BMI 34.6 ± 6.4 Kg/m²; 36.7% naïve to diabetes treatment, 43.3% on metformin, 10.0% on dual oral therapy, and 10.0% treated with schemes including insulin) were included in the study.
Show in the study text Report a problemFND-3901518604
05HumanObservational studyEfficacy outcome
In adults with type 2 diabetes, lean mass fell significantly by over 3 kg at both 6 and 12 months of semaglutide.
In plain wordsIn adults with type 2 diabetes, lean body mass was lower after 6 and 12 months of semaglutide.
Peptide
Semaglutide
Outcome
DecreaseLean mass change at 6 and 12 months
Study
n = 90
Comparator
Baseline
Outcome group
Body composition · Metabolic and weight
Studied dose
Dose not stated · subcutaneous · 6 and 12 monthsAs given in this study (human).
Measurements
Lean mass change
> 3 Kg
6 and 12 months
Source sentences
Summary
At BIA, fat mass was significantly reduced by 2.1 Kg after 6 months but only slightly reduced after 12 months vs. baseline; lean mass was also significantly reduced by over 3 Kg both at 6 and 12 months.
2 context sentences(design, population, supporting numbers)
Summary · context
This observational, prospective clinical study involved all T2D patients starting ow semaglutide according to routine care between December 2021 and February 2022.
Summary · context
Overall, 90 patients (age 63.0 ± 10.0 years; diabetes duration 7.6 ± 5.9 years; 58.9% men; HbA1c 7.7 ± 1.1%; weight 95.4 ± 19.4 Kg, BMI 34.6 ± 6.4 Kg/m²; 36.7% naïve to diabetes treatment, 43.3% on metformin, 10.0% on dual oral therapy, and 10.0% treated with schemes including insulin) were included in the study.
Show in the study text Report a problemFND-3901518605
06HumanObservational studyEfficacy outcome
In adults with type 2 diabetes, lipid intake fell significantly by 6.73 g in the first 6 months of semaglutide.
In plain wordsIn adults with type 2 diabetes, people ate less fat in the first 6 months of semaglutide.
Peptide
Semaglutide
Outcome
DecreaseLipid intake change in the first 6 months
Study
n = 90
Comparator
Baseline
Outcome group
Appetite and food intake · Metabolic and weight
Studied dose
Dose not stated · subcutaneous · 6 monthsAs given in this study (human).
Measurements
Lipid intake change
−6.73 g
6 months
Source sentences
Summary
Intake of all nutrients declined in the first 6 months of therapy, although only lipids reduction reached the statistical significance (-6.73 g; p=0.02).
2 context sentences(design, population, supporting numbers)
Summary · context
This observational, prospective clinical study involved all T2D patients starting ow semaglutide according to routine care between December 2021 and February 2022.
Summary · context
Overall, 90 patients (age 63.0 ± 10.0 years; diabetes duration 7.6 ± 5.9 years; 58.9% men; HbA1c 7.7 ± 1.1%; weight 95.4 ± 19.4 Kg, BMI 34.6 ± 6.4 Kg/m²; 36.7% naïve to diabetes treatment, 43.3% on metformin, 10.0% on dual oral therapy, and 10.0% treated with schemes including insulin) were included in the study.
Show in the study text Report a problemFND-3901518606
07HumanObservational studyEfficacy outcome
In adults with type 2 diabetes, intake of nutrients other than lipids declined in the first 6 months of semaglutide but not significantly.
In plain wordsIn adults with type 2 diabetes, intake of other nutrients fell a little in the first 6 months of semaglutide, but not significantly.
Peptide
Semaglutide
Outcome
No significant changeIntake of other nutrients in the first 6 months
Study
n = 90
Comparator
Baseline
Outcome group
Appetite and food intake · Metabolic and weight
Studied dose
Dose not stated · subcutaneous · 6 monthsAs given in this study (human).
Source sentences
Summary
Intake of all nutrients declined in the first 6 months of therapy, although only lipids reduction reached the statistical significance (-6.73 g; p=0.02).
2 context sentences(design, population, supporting numbers)
Summary · context
This observational, prospective clinical study involved all T2D patients starting ow semaglutide according to routine care between December 2021 and February 2022.
Summary · context
Overall, 90 patients (age 63.0 ± 10.0 years; diabetes duration 7.6 ± 5.9 years; 58.9% men; HbA1c 7.7 ± 1.1%; weight 95.4 ± 19.4 Kg, BMI 34.6 ± 6.4 Kg/m²; 36.7% naïve to diabetes treatment, 43.3% on metformin, 10.0% on dual oral therapy, and 10.0% treated with schemes including insulin) were included in the study.
Show in the study text Report a problemFND-3901518607
08HumanObservational studyEfficacy outcome
In adults with type 2 diabetes, BMI improved significantly during semaglutide treatment.
In plain wordsIn adults with type 2 diabetes, BMI improved during semaglutide treatment.
Peptide
Semaglutide
Outcome
DecreaseBMI change
Study
n = 90
Comparator
Baseline
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · subcutaneousAs given in this study (human).
Source sentences
Summary
Statistically significant improvements in BMI, waist circumference, glycemic control, blood pressure and lipid profile were documented.
2 context sentences(design, population, supporting numbers)
Summary · context
This observational, prospective clinical study involved all T2D patients starting ow semaglutide according to routine care between December 2021 and February 2022.
Summary · context
Overall, 90 patients (age 63.0 ± 10.0 years; diabetes duration 7.6 ± 5.9 years; 58.9% men; HbA1c 7.7 ± 1.1%; weight 95.4 ± 19.4 Kg, BMI 34.6 ± 6.4 Kg/m²; 36.7% naïve to diabetes treatment, 43.3% on metformin, 10.0% on dual oral therapy, and 10.0% treated with schemes including insulin) were included in the study.
Show in the study text Report a problemFND-3901518608
09HumanObservational studyEfficacy outcome
In adults with type 2 diabetes, waist circumference improved significantly during semaglutide treatment.
In plain wordsIn adults with type 2 diabetes, waist size improved during semaglutide treatment.
Peptide
Semaglutide
Outcome
DecreaseWaist circumference change
Study
n = 90
Comparator
Baseline
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · subcutaneousAs given in this study (human).
Source sentences
Summary
Statistically significant improvements in BMI, waist circumference, glycemic control, blood pressure and lipid profile were documented.
2 context sentences(design, population, supporting numbers)
Summary · context
This observational, prospective clinical study involved all T2D patients starting ow semaglutide according to routine care between December 2021 and February 2022.
Summary · context
Overall, 90 patients (age 63.0 ± 10.0 years; diabetes duration 7.6 ± 5.9 years; 58.9% men; HbA1c 7.7 ± 1.1%; weight 95.4 ± 19.4 Kg, BMI 34.6 ± 6.4 Kg/m²; 36.7% naïve to diabetes treatment, 43.3% on metformin, 10.0% on dual oral therapy, and 10.0% treated with schemes including insulin) were included in the study.
Show in the study text Report a problemFND-3901518609
10HumanObservational studyEfficacy outcome
In adults with type 2 diabetes, glycemic control improved significantly during semaglutide treatment.
In plain wordsIn adults with type 2 diabetes, blood sugar control improved during semaglutide treatment.
Peptide
Semaglutide
Outcome
Direction not reportedGlycemic control
Study
n = 90
Comparator
Baseline
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · subcutaneousAs given in this study (human).
Source sentences
Summary
Statistically significant improvements in BMI, waist circumference, glycemic control, blood pressure and lipid profile were documented.
2 context sentences(design, population, supporting numbers)
Summary · context
This observational, prospective clinical study involved all T2D patients starting ow semaglutide according to routine care between December 2021 and February 2022.
Summary · context
Overall, 90 patients (age 63.0 ± 10.0 years; diabetes duration 7.6 ± 5.9 years; 58.9% men; HbA1c 7.7 ± 1.1%; weight 95.4 ± 19.4 Kg, BMI 34.6 ± 6.4 Kg/m²; 36.7% naïve to diabetes treatment, 43.3% on metformin, 10.0% on dual oral therapy, and 10.0% treated with schemes including insulin) were included in the study.
Show in the study text Report a problemFND-3901518610
11HumanObservational studyEfficacy outcome
In adults with type 2 diabetes, blood pressure improved significantly during semaglutide treatment.
In plain wordsIn adults with type 2 diabetes, blood pressure improved during semaglutide treatment.
Peptide
Semaglutide
Outcome
Direction not reportedBlood pressure
Study
n = 90
Comparator
Baseline
Outcome group
Blood pressure · Cardiovascular
Studied dose
Dose not stated · subcutaneousAs given in this study (human).
Source sentences
Summary
Statistically significant improvements in BMI, waist circumference, glycemic control, blood pressure and lipid profile were documented.
2 context sentences(design, population, supporting numbers)
Summary · context
This observational, prospective clinical study involved all T2D patients starting ow semaglutide according to routine care between December 2021 and February 2022.
Summary · context
Overall, 90 patients (age 63.0 ± 10.0 years; diabetes duration 7.6 ± 5.9 years; 58.9% men; HbA1c 7.7 ± 1.1%; weight 95.4 ± 19.4 Kg, BMI 34.6 ± 6.4 Kg/m²; 36.7% naïve to diabetes treatment, 43.3% on metformin, 10.0% on dual oral therapy, and 10.0% treated with schemes including insulin) were included in the study.
Show in the study text Report a problemFND-3901518611
12HumanObservational studyEfficacy outcome
In adults with type 2 diabetes, the lipid profile improved significantly during semaglutide treatment.
In plain wordsIn adults with type 2 diabetes, blood fat levels improved during semaglutide treatment.
Peptide
Semaglutide
Outcome
Direction not reportedLipid profile
Study
n = 90
Comparator
Baseline
Outcome group
Lipids · Cardiovascular
Studied dose
Dose not stated · subcutaneousAs given in this study (human).
Source sentences
Summary
Statistically significant improvements in BMI, waist circumference, glycemic control, blood pressure and lipid profile were documented.
2 context sentences(design, population, supporting numbers)
Summary · context
This observational, prospective clinical study involved all T2D patients starting ow semaglutide according to routine care between December 2021 and February 2022.
Summary · context
Overall, 90 patients (age 63.0 ± 10.0 years; diabetes duration 7.6 ± 5.9 years; 58.9% men; HbA1c 7.7 ± 1.1%; weight 95.4 ± 19.4 Kg, BMI 34.6 ± 6.4 Kg/m²; 36.7% naïve to diabetes treatment, 43.3% on metformin, 10.0% on dual oral therapy, and 10.0% treated with schemes including insulin) were included in the study.
Show in the study text Report a problemFND-3901518612
13HumanObservational studyEfficacy outcome
In adults with type 2 diabetes, treatment satisfaction measured by the DTSQ increased significantly during semaglutide follow-up.
In plain wordsIn adults with type 2 diabetes, satisfaction with treatment rose during semaglutide follow-up.
Peptide
Semaglutide
Outcome
IncreaseTreatment satisfaction (DTSQ)
Study
n = 90
Comparator
Baseline
Outcome group
Patient-reported outcomes · Mental health and mood
Studied dose
Dose not stated · subcutaneousAs given in this study (human).
Source sentences
Summary
Satisfaction with treatment (DTSQ questionnaire) and mental health (MCS score of SF-36 questionnaire) significantly increased during the follow-up.
2 context sentences(design, population, supporting numbers)
Summary · context
This observational, prospective clinical study involved all T2D patients starting ow semaglutide according to routine care between December 2021 and February 2022.
Summary · context
Overall, 90 patients (age 63.0 ± 10.0 years; diabetes duration 7.6 ± 5.9 years; 58.9% men; HbA1c 7.7 ± 1.1%; weight 95.4 ± 19.4 Kg, BMI 34.6 ± 6.4 Kg/m²; 36.7% naïve to diabetes treatment, 43.3% on metformin, 10.0% on dual oral therapy, and 10.0% treated with schemes including insulin) were included in the study.
Show in the study text Report a problemFND-3901518613
14HumanObservational studyEfficacy outcome
In adults with type 2 diabetes, the SF-36 mental component score increased significantly during semaglutide follow-up.
In plain wordsIn adults with type 2 diabetes, a mental health score rose during semaglutide follow-up.
Peptide
Semaglutide
Outcome
IncreaseMental health score (SF-36 MCS)
Study
n = 90
Comparator
Baseline
Outcome group
Patient-reported outcomes · Mental health and mood
Studied dose
Dose not stated · subcutaneousAs given in this study (human).
Source sentences
Summary
Satisfaction with treatment (DTSQ questionnaire) and mental health (MCS score of SF-36 questionnaire) significantly increased during the follow-up.
2 context sentences(design, population, supporting numbers)
Summary · context
This observational, prospective clinical study involved all T2D patients starting ow semaglutide according to routine care between December 2021 and February 2022.
Summary · context
Overall, 90 patients (age 63.0 ± 10.0 years; diabetes duration 7.6 ± 5.9 years; 58.9% men; HbA1c 7.7 ± 1.1%; weight 95.4 ± 19.4 Kg, BMI 34.6 ± 6.4 Kg/m²; 36.7% naïve to diabetes treatment, 43.3% on metformin, 10.0% on dual oral therapy, and 10.0% treated with schemes including insulin) were included in the study.
Show in the study text Report a problemFND-3901518614

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
11 Oct 2026, 00:04 UTC
Study results updated
Version 1
9 Oct 2026, 03:06 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.

Changes in body weight and composition, metabolic parameters, and quality of life in patients with type 2 diabetes treated with subcutaneous semaglutide in real-world clinical practice.

Summary

Results from this study14

Version history

Subjects

Publication types

MeSH terms

Keywords